[go: up one dir, main page]

WO2001068141A8 - Dispersions de conjugues polypeptidiques - Google Patents

Dispersions de conjugues polypeptidiques

Info

Publication number
WO2001068141A8
WO2001068141A8 PCT/DK2001/000182 DK0100182W WO0168141A8 WO 2001068141 A8 WO2001068141 A8 WO 2001068141A8 DK 0100182 W DK0100182 W DK 0100182W WO 0168141 A8 WO0168141 A8 WO 0168141A8
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
group
characteristic
dispersion
amino acid
Prior art date
Application number
PCT/DK2001/000182
Other languages
English (en)
Other versions
WO2001068141A2 (fr
Inventor
Christian Karsten Hansen
Original Assignee
Maxygen Aps
Christian Karsten Hansen
Maxygen Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/DK2000/000471 external-priority patent/WO2001015736A2/fr
Priority claimed from PCT/DK2000/000631 external-priority patent/WO2001036001A2/fr
Application filed by Maxygen Aps, Christian Karsten Hansen, Maxygen Holdings Ltd filed Critical Maxygen Aps
Priority to AU42310/01A priority Critical patent/AU4231001A/en
Publication of WO2001068141A2 publication Critical patent/WO2001068141A2/fr
Publication of WO2001068141A8 publication Critical patent/WO2001068141A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne de nouvelles dispersions d'un conjugué contenant une variante polypeptidique et un groupe caractéristique non polypeptidique, et la délivrance pulmonaire de quantités thérapeutiquement efficaces de cette dispersion pour le traitement de maladies. L'invention concerne également une dispersion de particules contenant un conjugué comprenant au moins un groupe caractéristique non polypeptidique fixé de façon covalente à une variante polypeptidique. La séquence d'acides aminés de cette variante polypeptidique diffère de celle du polypeptide humain de type sauvage correspondant en ce qu'au moins un résidu d'acide aminé comprenant un groupe de fixation de ce groupe caractéristique non polypeptidique a été introduit et/ou retiré. Des exemples des polypeptides humains de type sauvage contiennent des cytokines, des facteurs de croissance, des hormones et des activateurs plasminogènes.
PCT/DK2001/000182 2000-03-17 2001-03-16 Dispersions de conjugues polypeptidiques WO2001068141A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU42310/01A AU4231001A (en) 2000-03-17 2001-03-16 Dispersions of polypeptide conjugates

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
DKPA200000447 2000-03-17
DKPA200000447 2000-03-17
US19084400P 2000-03-20 2000-03-20
US60/190,844 2000-03-20
PCT/DK2000/000471 WO2001015736A2 (fr) 1999-08-27 2000-08-25 Nouvelles molecules analogues a l'interferon beta
DKPCT/DK00/00471 2000-08-25
DKPCT/DK00/00631 2000-11-13
PCT/DK2000/000631 WO2001036001A2 (fr) 1999-11-12 2000-11-13 Conjugues d'interferon gamma

Publications (2)

Publication Number Publication Date
WO2001068141A2 WO2001068141A2 (fr) 2001-09-20
WO2001068141A8 true WO2001068141A8 (fr) 2002-07-11

Family

ID=27439765

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2001/000182 WO2001068141A2 (fr) 2000-03-17 2001-03-16 Dispersions de conjugues polypeptidiques

Country Status (1)

Country Link
WO (1) WO2001068141A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
NZ529572A (en) 2001-05-21 2006-02-24 Nektar Therapeutics Pulmonary administration of chemically modified insulin
WO2004044006A1 (fr) * 2002-11-14 2004-05-27 Maxygen, Inc. Conjugues de l'interleukine-10 et de polymeres
CA3097443A1 (fr) * 2018-11-12 2020-05-22 I-Mab Biopharma Us Limited Proteines de fusion contenant des anticorps anti-cd47 et des cytokines

Also Published As

Publication number Publication date
WO2001068141A2 (fr) 2001-09-20

Similar Documents

Publication Publication Date Title
CA2624175C (fr) Antagonistes de peptide cgrp et conjugues
MA28975B1 (fr) Compositions et procedes de traitement de troubles neurologiques
US20080293626A1 (en) Pigment epithelium-derived factor as a therapeutic agent for vascular leakage
DK0831773T3 (da) Suspenderede peptid/proteinformuleringer
ATE383375T1 (de) Wti-modifiziertes peptid
US20060177452A1 (en) EphB receptor-binding peptides
WO2002048183A3 (fr) Compositions de cristaux de peptides
EP1111053A3 (fr) Fragment peptidique de la protéine g du virus respiratoire syncytial, agent immunogène, composition pharmaceutique le contentant et procédé de préparation
EP1798242A3 (fr) Anticorps anti-IGF-IR et leurs applications
PL361341A1 (pl) Nowa kompozycja farmaceutyczna
WO1998033509A3 (fr) Proprietes utiles de la lactoferrine humaine et de variants de celle-ci
PT662827E (pt) Metodos de diagnostico e composicoes farmaceuticas a base de proteinas notch e acidos nucleicos
EP0570916A3 (fr) Serumalbumine, humaine recombinante, procédé de préparation et composition pharmaceutique.
WO2001018550A3 (fr) Determination de proteines de liaison a am et association d'adrenomedulline (am)
IL104314A0 (en) Human kunitz-type protease inhibitor and variants thereof,their production and pharmaceutical compositions containing them
DE60231131D1 (de) Vakzine und verwendung davon zur behandlung amyotrophischer lateralsklerose
PT981362E (pt) Metodos de melhoramento do funcionamento do tracto gastrointestinal superior
WO2001068141A8 (fr) Dispersions de conjugues polypeptidiques
BG108111A (bg) Полимерни конюгати на неубластин и методи за тяхното използване
US20080200392A1 (en) Methods for Treating Parkinson's Disease
DK0721586T3 (da) Fremgangsmåder og sammensætninger til behandling af BCR/ABL-forbundne leukæmier og andre celleproliferationssygdomme
AU2001289034A1 (en) Novel pdes and uses thereof
ATE312179T1 (de) Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
US20040192589A1 (en) Production of high molecular mass lectins
WO2002007676A3 (fr) Composés à affinité pour le récepteur du facteur de stimulation des colonies de granulocytes (g-csfr)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

D17 Declaration under article 17(2)a
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP